尤瑞克林联合丁苯酞对急性进展性脑梗死患者脑红蛋白、胱抑素C及神经功能的影响  

The effect of urinary kallidinogenase combined with butylphthalide on the expressions of neuroglobin and cystatin C as well as neurological function in patients with acute progressive cerebral infarction

作　　者：江康[1] 姚尚莹 费裕朗 秦晓明 JIANG Kang;YAO Shang-ying;FEI Yu-lang;QIN Xiao-ming(The First Affiliated Hospital,Nanyang Medical College,Nanyang 473000,China;Fuwai Huazhong Cardiovascular Hospital,Zhengzhou 450000,China)

机构地区：[1]南阳医学高等专科学校第一附属医院,河南南阳473000 [2]阜外华中心血管病医院,河南郑州450000

出　　处：《实用医院临床杂志》2024年第4期107-111,共5页Practical Journal of Clinical Medicine

基　　金：河南省医学科技攻关计划项目(编号LHGJ20190779)。

摘　　要：目的 探讨尤瑞克林、丁苯酞联合治疗对急性进展性脑梗死(APCI)患者脑红蛋白、胱抑素C及神经功能的影响。方法 2020年12月至2021年12月南阳医学高等专科学校第一附属医院收治的APCI患者220例,按照随机数字表法分为观察组、尤瑞克林组、丁苯酞组、对照组各55例。对照组行对症综合治疗,丁苯酞组行对症综合治疗+静脉注射丁苯酞,尤瑞克林组行对症综合治疗+静脉注射尤瑞克林,观察组行对症综合治疗+丁苯酞+尤瑞克林治疗。四组均连续治疗2周,比较四组临床疗效,治疗前后血清脑红蛋白、胱抑素C及美国国立卫生研究院卒中量表(NIHSS)评分。结果 治疗后,四组脑红蛋白均高于治疗前,胱抑素C及NIHSS评分均低于治疗前(P<0.05);血清脑红蛋白水平:观察组>尤瑞克林组、丁苯酞组>对照组,胱抑素C及NIHSS评分:观察组<尤瑞克林组、丁苯酞组<对照组(P<0.05);尤瑞克林组与丁苯酞组的脑红蛋白、胱抑素C及NIHSS评分比较差异无统计学意义(P>0.05);观察组总有效率高于尤瑞克林组、丁苯酞组和对照组(P<0.05)。结论 尤瑞克林联合丁苯酞治疗APCI可显著提高患者血清脑红蛋白水平,降低血清胱抑素C水平及NIHSS评分,改善患者神经功能,提高临床疗效,具有一定的临床应用价值。Objective To explore the effect of urinary kallidinogenase combined with butylphthalide on the neuroglobin and cystatin C as well as neurological function in patients with acute progressive cerebral infarction(APCI).Methods A total of 220 patients with APCI admitted to the First Affiliated Hospital of Nanyang Medical College from December 2020 to December 2021 were selected.The patients were divided into an observation group,a kallidinogenase group,a butylphthalide group and a control group according to random number table method,55 in each group.The control group received comprehensive symptomatic treatment.The butylphthalide group received comprehensive symptomatic treatment+intravenous infusion of butylphthalide.The kalidinogenase group received comprehensive symptomatic treatment+intravenous infusion of kallidinogenase.The observation group received comprehensive symptomatic treatment+butylphthalide+kallidinogenase.All four groups were treated continuously for 2 weeks.The clinical effects and the scores of serum cerebral globin,cystatin C and NIHSS before and after treatment were compared among the four groups.Results After treatment,cerebral globin in all groups was higher than before treatment while cystatin C and NIHSS scores were lower than those before treatment(P<0.05).Serum cerebral globin level in the observation group was higher than that in the kallidinogenase group,the butylphthalide group and the control group while the cystatin C level and NIHSS scores in the observation group were lower than those in the kallidinogenase group,the butylphthalide group and the control group(P<0.05).There was no difference in the scores of cerebral globin,cystatin C and NIHSS between the kallidinogenase group and the butylphthalide group(P>0.05).The total effective rate of the observation group was higher than that of the kallidinogenase group,the butylphthalide group and the control group(P<0.05).Conclusions Urinary kallidinogenase combined with butylphthalide in the treatment of APCI can significantly increase th

关 键 词：尤瑞克林 丁苯酞 急性进展性脑梗死 脑红蛋白 胱抑素C 

分 类 号：R743.3[医药卫生—神经病学与精神病学]